AstraZeneca (LON:AZN) Receives Buy Rating from Shore Capital

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Monday morning, MarketBeat reports.

AZN has been the topic of a number of other research reports. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Berenberg Bank reiterated a buy rating on shares of AstraZeneca in a report on Wednesday, March 13th. UBS Group dropped their price objective on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating on the stock in a report on Monday, February 12th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a sell rating on shares of AstraZeneca in a research report on Tuesday, March 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of £115.43 ($143.69).

AstraZeneca Trading Down 0.1 %

AZN opened at £108.62 ($135.22) on Monday. AstraZeneca has a one year low of GBX 9,461 ($117.78) and a one year high of £123.92 ($154.26). The company has a market cap of £168.36 billion, a P/E ratio of 3,584.82, a PEG ratio of 0.89 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. The business’s 50-day simple moving average is £103.49 and its 200-day simple moving average is £104.25.

AstraZeneca Increases Dividend

The company also recently declared a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a dividend of GBX 156 ($1.94) per share. This is a positive change from AstraZeneca’s previous dividend of $71.80. The ex-dividend date was Thursday, February 22nd. This represents a yield of 1.49%. AstraZeneca’s payout ratio is 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.